April 23, 2019
Nippon Boehringer Ingelheim said on April 22 that it has filed an application seeking an additional indication for its tyrosine kinase inhibitor Ofev (nintedanib) for the treatment of interstitial lung disease (ILD) associated with systemic sclerosis. Ofev is a small-molecule...read more